Department of Health and Human Services, through National Institutes of Health, awarded Natsar Pharmaceuticals, Inc. of Ellicott City, MD $2,250,000 under the SBIR program (Phase II), with work starting 2025-09-22 and running to 2027-08-31. It is the only SBIR or STTR award to Natsar Pharmaceuticals, Inc. in the last two years. Each figure links to the federal record.
The award
| Recipient | Natsar Pharmaceuticals, Inc. (Ellicott City, MD) |
|---|---|
| Awarding agency | Department of Health and Human Services |
| Awarding office | National Institutes of Health |
| Phase | Phase II |
| Amount obligated | $2,250,000 |
| Period of performance starts | 2025-09-22 |
| Period of performance ends | 2027-08-31 |
| Award number | R44CA295155 (grant, CFDA 93.395) |
| Assistance listing | 93.395, Cancer Treatment Research |
| Place of performance | Ellicott City, Howard County, MD |
| Recipient registry id (UEI) | F2KMK7BBBMS3 |
Want the whole picture on Natsar Pharmaceuticals, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Natsar Pharmaceuticals, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Natsar Pharmaceuticals, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
1 cited source found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
What it is for
Drug development of RK-33 for breast cancer treatment - triple-negative breast cancers (tnbcs) are breast cancers that lack expression of estrogen receptor alpha, progesterone receptor, and HER2. They constitute approxim
Funding actions on this award
| Date | Action | Modification | Amount |
|---|---|---|---|
| 2026-09-17 | Continuation | 000 | $615,189 |
| 2025-09-22 | New | 000 | $1,634,811 |
Drug development of RK-33 for breast cancer treatment - triple-negative breast cancers (tnbcs) are breast cancers that lack expression of estrogen receptor alpha, progesterone receptor, and HER2. They constitute approximately 10-25% of all breast cancers and primarily affect younger women and african-american women. Even though the majority of patients with tnbc respond to neoadjuvant chemotherapy, they have a higher rate of distant recurrence and poor prognosis. The current treatment of tnbc is inadequate due to a lack of targetable biomarkers and the heterogeneous nature of the disease. To overcome the current treatment limitations, we need to uncover the mechanisms underlying tnbc biogenesis to generate targeted therapies. We found that a member of the RNA helicase family, DDX3, is dysregulated in breast tumors and is implicated in cancer establishment and metastasis. Importantly, we found DDX3 to be overexpressed in a significantly high percentage in breast cancer metastases, indicating that there is a dependency on DDX3 to maintain their malignant properties (non-oncogene addiction) and high DDX3 expression may help cells adapt to the metastatic microenvironment. Natsar pharmaceuticals, inc. (natsar) was founded to commercialize RK-33 as a therapeutic candidate for treating tnbc. We used a rational drug design approach to develop a small molecule inhibitor of DDX3, designa ...
From the federal award record.
More on Natsar Pharmaceuticals, Inc.
Natsar Pharmaceuticals, Inc.'s Form D filing
Who runs it, who owns it, where the money comes from and what to watch for, every claim linked to its source.
Order Full Report on Natsar Pharmaceuticals, Inc.Look up Natsar Pharmaceuticals, Inc. and see what is on record before you decide.
Get the free SnapshotWhere this comes from
The Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs set aside part of federal research budgets for small companies. Agencies award them in phases: Phase I tests whether an idea is feasible, Phase II funds development, and Phase III is follow-on work paid for outside the set-aside. STTR awards also require a research institution as a partner.
Every figure on this page is taken from the award's own federal record, linked beside it, as it stood when the page was built: the recipient, its address, the awarding agency and office, the amount obligated so far, the dates and the description. Phase and program are shown as the award's own description states them. The amount can grow later if the agency adds funding to the same award.